Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 32.65 as of 2026-10-06T12:50:18.719Z.
Consensus retrieved: 2026-10-06T08:18:41.952Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:50:18.719Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ecad0762b01eca72400a5d6f6e26675042e53628e137481382d213c8e973aca5
Forward PE Ratio (32.65) = Dated Quote Price ($20.11) / Consensus Forward EPS ($0.62)
FORWARD PE RATIO
32.65
SECTOR MEDIAN · HEALTHCARE
19.38
median of 131 covered companies
CURRENT VS SECTOR MEDIAN
+68.47%
vs the sector median at left
Acadia Pharmaceuticals Inc.
Market Cap
$3.44B
Forward PE Ratio
32.65
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.44B | 32.65 |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A |
| CareDx, Inc (CDNA)vs › | $3.61B | 58.32 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 50.59 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 56.57 |
Trailing P/E
9.1
reported TTM EPS
Forward P/E
32.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.62 implies -72.1% EPS decline vs the reported trailing $2.22.
At the dated quote price of $20.11, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.62 | $0.45 – $0.84 | 13 | 32.6x |
| 2027-12-31 | $0.93 | $0.47 – $1.77 | 13 | 21.7x |
| 2028-12-31 | $1.54 | $0.88 – $3.00 | 13 | 13.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
